Alix Jacquier
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Alix Jacquier has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Clément Dumont
Department of Medical Oncology, Hôpital Saint Louis, AP-HP, Paris, France
12 shared publications - Joel LeMaoult
Hemato-Immunology Research Department, CEA, DRF-Francois Jacob Institute, Saint-Louis Hospital, Paris, France - U976 HIPI Unit, IRSL, Paris University, Paris, France
12 shared publications - Nathalie Rouas-Freiss
CEA, Institut des Maladies Émergentes et des Thérapies Innovantes (iMETI), Service de Recherche en Hémato-Immunologie (SRHI), Hôpital Saint-Louis, Avenue Claude Vellefaux 1, 75010 Paris, France
9 shared publications - Alexandra Masson-Lecomte
Saint-Louis Hospital 1 Hemato-Immunology Research Department, CEA, DRF-Francois Jacob Institute Paris, France
8 shared publications - Dzenis Koca
INSERM 4 Interdisciplinary Research Institute of Grenoble, IRIG-Biosanté, University Grenoble Alpes, CEA UMR 1292, Grenoble, France
8 shared publications - Edgardo D. Carosella
Saint-Louis Hospital 1 Hemato-Immunology Research Department, CEA, DRF-Francois Jacob Institute Paris, France
8 shared publications
Latest Publications
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from ILT2 Identifies an Unexploited Pool of Intratumoral CD8+ Bystander T Cells with TCR-Independent Cytotoxicity in Renal Cell Carcinoma
Fig. S3. Transcriptomic characterization of the CD8+ILT2+ T cell subset
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from ILT2 Identifies an Unexploited Pool of Intratumoral CD8+ Bystander T Cells with TCR-Independent Cytotoxicity in Renal Cell Carcinoma
Fig. S3. Transcriptomic characterization of the CD8+ILT2+ T cell subset
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from ILT2 Identifies an Unexploited Pool of Intratumoral CD8+ Bystander T Cells with TCR-Independent Cytotoxicity in Renal Cell Carcinoma
Fig. S2. Quantitative analysis of spectral flow cytometry clusters.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from ILT2 Identifies an Unexploited Pool of Intratumoral CD8+ Bystander T Cells with TCR-Independent Cytotoxicity in Renal Cell Carcinoma
Fig. S2. Quantitative analysis of spectral flow cytometry clusters.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from ILT2 Identifies an Unexploited Pool of Intratumoral CD8+ Bystander T Cells with TCR-Independent Cytotoxicity in Renal Cell Carcinoma
Fig. S5. CD8+ILT2+ T cells display TCR-independent cytotoxicity selectively toward NKG2D ligand-expressing target cells.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from ILT2 Identifies an Unexploited Pool of Intratumoral CD8+ Bystander T Cells with TCR-Independent Cytotoxicity in Renal Cell Carcinoma
Fig. S5. CD8+ILT2+ T cells display TCR-independent cytotoxicity selectively toward NKG2D ligand-expressing target cells.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from ILT2 Identifies an Unexploited Pool of Intratumoral CD8+ Bystander T Cells with TCR-Independent Cytotoxicity in Renal Cell Carcinoma
Fig. S4. CD8+ILT2− T cells do not exhibit TCR-independent cytotoxic potential.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from ILT2 Identifies an Unexploited Pool of Intratumoral CD8+ Bystander T Cells with TCR-Independent Cytotoxicity in Renal Cell Carcinoma
Fig. S4. CD8+ILT2− T cells do not exhibit TCR-independent cytotoxic potential.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from ILT2 Identifies an Unexploited Pool of Intratumoral CD8+ Bystander T Cells with TCR-Independent Cytotoxicity in Renal Cell Carcinoma
Fig. S1. Association of the HLA-G/ILT2 and PD-L1/PD1 checkpoints with clinical parameters in ccRCC.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from ILT2 Identifies an Unexploited Pool of Intratumoral CD8+ Bystander T Cells with TCR-Independent Cytotoxicity in Renal Cell Carcinoma
Fig. S1. Association of the HLA-G/ILT2 and PD-L1/PD1 checkpoints with clinical parameters in ccRCC.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Data from ILT2 Identifies an Unexploited Pool of Intratumoral CD8+ Bystander T Cells with TCR-Independent Cytotoxicity in Renal Cell Carcinoma
Immune checkpoint inhibitors (ICI) have improved clear-cell renal cell carcinoma (ccRCC) therapy, yet many patients remain unresponsive. Alternative strategies are needed, and the HLA-G/ILT2 axis has emerged as a promising immunosuppressive pathway. In this study, we deeply characterized CD8+ILT2+ tumor-infiltrating lymphocytes (TIL) as a distinct subset from CD8+PD-1+ TILs in ccRCC, using high-dimensional spectral flow cytometry, single-cell transcriptomics, and T-cell receptor (TCR) clonotype analysis. CD8+ILT2+ TILs were terminally differentiated, highly cytotoxic “bystander” cells, enriched for virus-specific TCRs. They phenotypically, transcriptionally, and functionally mirrored their circulating counterparts, suggesting peripheral recruitment. In dynamic coculture assays, they exhibited potent TCR-independent cytotoxicity, mediated by activating innate receptors, namely NKG2D. However, HLA-G inhibited this activity, underscoring the immune-evasive role of the HLA-G/ILT2 axis. Our study defines CD8+ILT2+ TILs as an untapped effector population with potential antitumor activity and a promising therapeutic target in ccRCC. These findings offer new insights into TIL functional diversity and pave the way for innovative immunotherapies beyond conventional ICIs.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from ILT2 Identifies an Unexploited Pool of Intratumoral CD8+ Bystander T Cells with TCR-Independent Cytotoxicity in Renal Cell Carcinoma
Immune checkpoint inhibitors (ICI) have improved clear-cell renal cell carcinoma (ccRCC) therapy, yet many patients remain unresponsive. Alternative strategies are needed, and the HLA-G/ILT2 axis has emerged as a promising immunosuppressive pathway. In this study, we deeply characterized CD8+ILT2+ tumor-infiltrating lymphocytes (TIL) as a distinct subset from CD8+PD-1+ TILs in ccRCC, using high-dimensional spectral flow cytometry, single-cell transcriptomics, and T-cell receptor (TCR) clonotype analysis. CD8+ILT2+ TILs were terminally differentiated, highly cytotoxic “bystander” cells, enriched for virus-specific TCRs. They phenotypically, transcriptionally, and functionally mirrored their circulating counterparts, suggesting peripheral recruitment. In dynamic coculture assays, they exhibited potent TCR-independent cytotoxicity, mediated by activating innate receptors, namely NKG2D. However, HLA-G inhibited this activity, underscoring the immune-evasive role of the HLA-G/ILT2 axis. Our study defines CD8+ILT2+ TILs as an untapped effector population with potential antitumor activity and a promising therapeutic target in ccRCC. These findings offer new insights into TIL functional diversity and pave the way for innovative immunotherapies beyond conventional ICIs.
- 8 July 2026
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 14 (8) , OF1-OF16
ILT2 Identifies an Unexploited Pool of Intratumoral CD8+ Bystander T Cells with TCR-Independent Cytotoxicity in Renal Cell Carcinoma
Immune checkpoint inhibitors (ICI) have improved clear-cell renal cell carcinoma (ccRCC) therapy, yet many patients remain unresponsive. Alternative strategies are needed, and the HLA-G/ILT2 axis has emerged as a promising immunosuppressive pathway. In this study, we deeply characterized CD8+ILT2+ tumor-infiltrating lymphocytes (TIL) as a distinct subset from CD8+PD-1+ TILs in ccRCC, using high-dimensional spectral flow cytometry, single-cell transcriptomics, and T-cell receptor (TCR) clonotype analysis. CD8+ILT2+ TILs were terminally differentiated, highly cytotoxic “bystander” cells, enriched for virus-specific TCRs. They phenotypically, transcriptionally, and functionally mirrored their circulating counterparts, suggesting peripheral recruitment. In dynamic coculture assays, they exhibited potent TCR-independent cytotoxicity, mediated by activating innate receptors, namely NKG2D. However, HLA-G inhibited this activity, underscoring the immune-evasive role of the HLA-G/ILT2 axis. Our study defines CD8+ILT2+ TILs as an untapped effector population with potential antitumor activity and a promising therapeutic target in ccRCC. These findings offer new insights into TIL functional diversity and pave the way for innovative immunotherapies beyond conventional ICIs.
- 8 July 2026
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 14 (8) , OF1-OF16
ILT2 Identifies an Unexploited Pool of Intratumoral CD8+ Bystander T Cells with TCR-Independent Cytotoxicity in Renal Cell Carcinoma
Immune checkpoint inhibitors (ICI) have improved clear-cell renal cell carcinoma (ccRCC) therapy, yet many patients remain unresponsive. Alternative strategies are needed, and the HLA-G/ILT2 axis has emerged as a promising immunosuppressive pathway. In this study, we deeply characterized CD8+ILT2+ tumor-infiltrating lymphocytes (TIL) as a distinct subset from CD8+PD-1+ TILs in ccRCC, using high-dimensional spectral flow cytometry, single-cell transcriptomics, and T-cell receptor (TCR) clonotype analysis. CD8+ILT2+ TILs were terminally differentiated, highly cytotoxic “bystander” cells, enriched for virus-specific TCRs. They phenotypically, transcriptionally, and functionally mirrored their circulating counterparts, suggesting peripheral recruitment. In dynamic coculture assays, they exhibited potent TCR-independent cytotoxicity, mediated by activating innate receptors, namely NKG2D. However, HLA-G inhibited this activity, underscoring the immune-evasive role of the HLA-G/ILT2 axis. Our study defines CD8+ILT2+ TILs as an untapped effector population with potential antitumor activity and a promising therapeutic target in ccRCC. These findings offer new insights into TIL functional diversity and pave the way for innovative immunotherapies beyond conventional ICIs.
- 4 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Impact du checkpoint inhibiteur HLA-G/ILT2 sur la réponse immune anti-tumorale dans les cancers urologiques
Le développement de l'immunothérapie à travers l'inhibition des immune checkpoints a révolutionné le domaine de la cancérologie. Cependant, malgré l'efficacité de ces thérapies, certains patients demeurent résistants à ces traitements. L'expression hétérogène des immune checkpoints est une des hypothèses avancées pour expliquer cette résistance, il est donc crucial d'identifier de nouvelles cibles afin de combiner plusieurs thérapies. Dans ce contexte, l'expression du checkpoint inhibiteur HLA-G a été observée dans plusieurs lésions tumorales et en particulier dans les carcinomes rénaux à cellules claires (ccRCC), associée ou non à d'autres immune checkpoints. L'effet inhibiteur d'HLA-G sur les effecteurs immunitaires a déjà été démontré par plusieurs études, néanmoins afin d'identifier son impact directement sur les cellules immunitaires exprimant son récepteur ILT2, j'ai mis au point un protocole d'analyse basé sur la cytométrie en flux. Cette méthode nous a permis de caractériser sur le plan phénotypique et fonctionnel les lymphocytes T CD8+ ILT2+ et CD4+ILT2+ périphériques et infiltrants les ccRCC. Les lymphocytes T CD8+ILT2+ et CD4+ILT2+ présentent un phénotype mémoire terminal et fortement cytotoxique, et sont fonctionnellement inhibés lorsqu'HLA-G est exprimé par une cellule cible, comme c'est le cas des cellules tumorales. Dans un second temps je me suis intéressée à la relation ontogénique entre les cellules T CD8+PD1+ et CD8+ILT2+, ces derniers présentant un phénotype mémoire plus différencié que les premiers. En utilisant un protocole de stimulation in vitro dans un système de coculture autologue entre les lymphocytes infiltrants et les cellules tumorales, les résultats obtenus montrent que sous l'effet d'un inhibiteur de PD1/PD-L1 une population de LT CD8+ILT2+ pouvait émerger et proliférer. Dans le cas d'une immunothérapie ciblant PD1/PD-L1, les lymphocytes T CD8+PD1+ pourraient donc exprimer ILT2 et être alors inhibés par HLA-G exprimé par les cellules tumorales, ce qui conduirait à terme à un échec de la thérapie. L'objectif de ce travail est de démontrer à terme la relevance du checkpoint HLA-G/ILT2 comme nouvelle cible thérapeutique en oncoimmunologie.
- 4 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Impact du checkpoint inhibiteur HLA-G/ILT2 sur la réponse immune anti-tumorale dans les cancers urologiques
Le développement de l'immunothérapie à travers l'inhibition des immune checkpoints a révolutionné le domaine de la cancérologie. Cependant, malgré l'efficacité de ces thérapies, certains patients demeurent résistants à ces traitements. L'expression hétérogène des immune checkpoints est une des hypothèses avancées pour expliquer cette résistance, il est donc crucial d'identifier de nouvelles cibles afin de combiner plusieurs thérapies. Dans ce contexte, l'expression du checkpoint inhibiteur HLA-G a été observée dans plusieurs lésions tumorales et en particulier dans les carcinomes rénaux à cellules claires (ccRCC), associée ou non à d'autres immune checkpoints. L'effet inhibiteur d'HLA-G sur les effecteurs immunitaires a déjà été démontré par plusieurs études, néanmoins afin d'identifier son impact directement sur les cellules immunitaires exprimant son récepteur ILT2, j'ai mis au point un protocole d'analyse basé sur la cytométrie en flux. Cette méthode nous a permis de caractériser sur le plan phénotypique et fonctionnel les lymphocytes T CD8+ ILT2+ et CD4+ILT2+ périphériques et infiltrants les ccRCC. Les lymphocytes T CD8+ILT2+ et CD4+ILT2+ présentent un phénotype mémoire terminal et fortement cytotoxique, et sont fonctionnellement inhibés lorsqu'HLA-G est exprimé par une cellule cible, comme c'est le cas des cellules tumorales. Dans un second temps je me suis intéressée à la relation ontogénique entre les cellules T CD8+PD1+ et CD8+ILT2+, ces derniers présentant un phénotype mémoire plus différencié que les premiers. En utilisant un protocole de stimulation in vitro dans un système de coculture autologue entre les lymphocytes infiltrants et les cellules tumorales, les résultats obtenus montrent que sous l'effet d'un inhibiteur de PD1/PD-L1 une population de LT CD8+ILT2+ pouvait émerger et proliférer. Dans le cas d'une immunothérapie ciblant PD1/PD-L1, les lymphocytes T CD8+PD1+ pourraient donc exprimer ILT2 et être alors inhibés par HLA-G exprimé par les cellules tumorales, ce qui conduirait à terme à un échec de la thérapie. L'objectif de ce travail est de démontrer à terme la relevance du checkpoint HLA-G/ILT2 comme nouvelle cible thérapeutique en oncoimmunologie.